Boxer Capital Management has made a notable entry into the biotechnology sector by acquiring 1,100,000 shares of Corvus Pharmaceuticals (NASDAQ: CRVS) in the first quarter, valued at approximately $17.55 million. This new position represents about 2.11% of Boxer’s reportable assets under management as of March 31, 2026, with a quarter-end valuation of $16.09 million, reflecting the stock’s price fluctuations during the period.

Corvus Pharmaceuticals has seen a remarkable 250% increase in its share price over the past year, significantly outperforming the S&P 500’s 25% gain. The company focuses on developing immuno-oncology therapies and has generated renewed interest with promising Phase 1 data on its treatments for atopic dermatitis. With $236.7 million in cash and marketable securities, Corvus is well-positioned to fund its operations through mid-2028, despite a recent quarterly net loss of $13.7 million due to rising R&D costs.

For investors, Boxer’s substantial investment could signal confidence in Corvus’s long-term potential, particularly as the company advances its clinical trials. However, with analysts suggesting alternative stocks may offer better returns, market professionals should weigh Boxer’s endorsement against broader investment strategies before making decisions regarding Corvus.

Source: nasdaq.com